Friday 6 November 2026 Export KNSA’s income statement to Excel — free account

Kiniksa Pharmaceuticals International, plc

KNSA Healthcare Drug Manufacturers Specialty & Generic

Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024.

Revenue: +58.1%
EPS: +142.2%
Free cash flow: +43.5%

Quarter to September 2026, against a year earlier

88.50 7.62 −7.93%

Follow KNSA

Alert me

Market cap: $6.9B
P/E: 62.1×
Fwd P/E: 67.8×
Dividend yield: —
F-score: 8/9
Altman Z: 10.35
Beneish M: −3.16
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Kiniksa Pharmaceuticals International, plc (KNSA) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Kiniksa Pharmaceuticals International, plc (KNSA) trades at a P/S ratio of 7.3×. Over the past ten years it has ranged from 0.0× (March 2022) to 11.2× (April 2022); the current reading is higher than 93% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.1× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/KNSA/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Kiniksa Pharmaceuticals International, plc P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/KNSA/metrics/ps-ratio">Kiniksa Pharmaceuticals International, plc (KNSA) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	4.5×	35.33%
FY2024	3.3×	(30.51%)
FY2023	4.8×	5.56%
FY2022	4.6×	—
FY2021	0.0×	—

Period	P/S ratio	Change
Sep 2026	6.2×	4.53%
Jun 2026	5.9×	20.76%
Mar 2026	4.9×	8.16%
Dec 2025	4.5×	(6.89%)
18 more quarters	Free account

Against its own ten years

Low 0.0× High 11.2×

Ten-year median 3.5×

Current reading's percentile 88

Company	P/S ratio
AMRX AMNEAL PHARMACEUTICALS, INC. compare	2.0×
HIMS Hims & Hers Health, Inc. compare	2.2×
ELAN Elanco Animal Health Incorporated compare	2.4×
SUPN Indivior Pharmaceuticals Inc. compare	2.4×
RDY Dr. Reddy's Laboratories Ltd compare	3.6×
LNTH Lantheus Holdings, Inc. compare	4.2×
ALKS Alkermes plc compare	4.3×
KNSA Kiniksa Pharmaceuticals International, plc	7.3×
LQDA Liquidia Corporation compare	8.8×
Drug Manufacturers Specialty & Generic industry median	2.1×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Kiniksa Pharmaceuticals International, plc (KNSA) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on KNSA

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on KNSA

Stockrow Weekly